Zymeworks Added to Nasdaq Biotechnology Index

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average daily trading volume, and seasoning as a public company. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology. The NBI is currently comprised of approximately 250 companies. For more information about the NBI, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the anticipated inclusion in the Nasdaq Biotechnology Index following the annual reconstitution, risks and uncertainties relating to the anticipated trading of Zymeworks securities, and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: risks relating to becoming included and remaining included in the Nasdaq Biotechnology Index; risks and uncertainties relating to the trading of our securities as it relates to the Nasdaq Biotechnology Index annual reconstitution and the inclusion of Zymeworks on the Nasdaq Biotechnology Index following such reconstitution; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; inability to maintain or enter into new partnerships or strategic collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; and the other risks described under “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended September 30, 2023 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:

Diana Papove
Director, Corporate Communications
(604) 678-1388
media@zymeworks.com



Zymeworks Added to Nasdaq Biotechnology Index

THỦ THUẬT HAY

Lấy lại tính năng Night Light cho Android 8.0 Oreo trên Nexus

Thật thiệt thòi cho những người sử dụng phiên bản Android 8.0 Oreo trên thiết bị Nexus vì nó thiếu một số tính năng. Một trong những tính năng mà Pixel sở hữu nhưng Nexus lại không có đó chính là 'Night Light'.

Hơn 100 bài tập Python có lời giải(code mẫu )

Hơn 100 bài tập Python kèm code mẫu được anh chàng zhiwehu chia sẻ trên Github, tuy nhiên, lời giải của loạt bài tập này được viết trên phiên bản Python đã cũ. Sau đây Quản Trị Mạng sẽ Việt hóa và chỉnh sửa để phù hợp

Xem phim miễn phí server vip trên HDOnlin không cần tài khoản Vip

Bạn muốn xem phim trên HDOnline.vn không giới hạn, full HD, đường truyền riêng cho VIP và không bị quảng cáo làm phiền... thay vì sử dụng tài khoản miễn phí

Các tính năng hấp dẫn của ứng dụng Gmail cho iPhone

Tuy nhiên nếu không thường xuyên cập nhật bạn sẽ không nhận ra những thay đổi thú vị qua từng lần nâng cấp phiên bản Gmail. Hãy theo dõi bài viết này để nhanh chóng trang bị cho mình những tính năng tuyệt vời này để sử

Những mẹo hay giúp chụp được những bức ảnh đẹp ngay tức khắc

Đôi khi một tấm hình đẹp có thể bị phá hỏng bởi các chi tiết thừa và vô duyên, ví dụ như chiếc cột trong hình minh hoạ phía trên chẳng hạn. Ban đầu, bạn có thể không quá để ý đến nó nhưng khi xem kĩ lại tác phẩm của

ĐÁNH GIÁ NHANH

Honda PCX 2018: Xe ga phổ thông có tư thế ngồi lái thoải mái nhất hiện nay

Được biết đến như một mẫu xe tay ga có ngoại hình to lớn với ngôn ngữ thiết kế cũng khá đặc biệt nhưng được cho là khá 'già' và chỉ phù hợp cho những đối tượng trung niên. ở mẫu Honda PCX 2018, tuy chiếc xe cũng sở hữu

Sony Xperia XZ3 liệu có phải là phiên bản nâng cấp đáng giá?

Hồi tháng 2 Sony Xperia XZ2 được ra mắt với thiết kế mới và phần cứng mạnh mẽ. Khoảng nửa năm sau, công ty Nhật Bản tiếp tục giới thiệu mẫu flagship tiếp theo có tên gọi Sony Xperia XZ3. Liệu phiên bản nâng cấp này có

So sánh Samsung Galaxy S21 Ultra và iPhone 13 Pro Max

Samsung và Apple là hai thương hiệu sở hữu những mẫu smartphone mạnh mẽ nhất hiện nay. Nổi bật nhất phải kể đến là Galaxy S21 Ultra và iPhone 13 Pro Max. Vậy giữa hai điện thoại này, “ai” nào xứng đáng trở thành ông